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What is a neurometabolic disease?
Among the growing list of genetic diseases, inborn errors of metabolism (IEM) are historically defined by enzymatic deficiencies or defects in proteins involved in cellular metabolism. This implies the use of specific strategies to diagnose and treat IEM. Likewise, before the confirmation by molecular analyses, the diagnostic of several IEM can be greatly facilitated by biochemical testing showing abnormal metabolites concentration or enzymatic activities. The recognition of IEM is even more important as some of them can be treated through enzyme replacement therapy or cofactors that increase enzymatic activity, the ophthalmoplegia with multiple mitochondrial DNA deletion on muscle biopsy [2] . The possibility for a given gene to be associated with both dominant (heterozygous mutation) and recessive (homozygous or composite heterozygous mutations) inheritance is, as a matter of fact, reported in a growing number of neurometabolic disorders [3] . Therefore, while certain biochemical tools are preferentially used for the diagnosis of certain subgroups of IEM - i.e. ammonemia in urea cycle defects -, it seems increasingly relevant to identify common cellular pathways between metabolic partners -such as OPA1 and SPG7 which proteins are both localized at the internal mitochondrial membrane -in order to gain knowledge in the pathophysiology underlying adult neurometabolic diseases. Several reviews on IEM in adults have been published [4, 5] . The purpose of this outline is to provide simple diagnostic tools and therapeutic strategies to address the most frequent IEM in adult neurology.
What are the tools useful for the diagnosis of neurometabolic diseases?
First, one should be pay much attention to the clinical history and signs of the disease. This Although a common feature of NBIA is represented by iron accumulation, the biochemical pathways underlying these genetic defects rather involve lipid metabolism and membrane/organelles (mitochondria) remodeling, corroborating the idea that iron deposition may be only a secondary phenomenon [7] . Brain MRI is also critical to identify metabolic white matter diseases [8] . Besides MRI, the diagnosis of a neurometabolic disease can also be comforted by findings from electromyogram, fundoscopy and/or audiometry due to the frequent involvement of multiple systems in IEM. Overall, axonal neuropathies are more common in metabolic diseases resulting in energy deficiency - respiratory chain defects, pyruvate dehydrogenase deficiency, fatty acids oxidation defects, adult polyglucosan body disease -whereas demyelinating neuropathies are more suggestive of complex lipids metabolismmetachromatic leukodystrophy, Krabbe disease, cerebrotendinous xanthomatosis [9] .
Peroxisomal diseases also frequently manifest in adults with an axonal or demyelinating neuropathy associated with other neuropsychiatric symptoms. Of note, pure sensory neuronopathy are evocative of diseases affecting the maintenance of the mitochondrial DNA, and especially POLG mutations. In addition, ophthalmological abnormalities are commonly observed in mitochondrial diseases (optic atrophy, retinitis pigmentosa) and peroxisomal diseases (cataract, retinitis pigmentosa). An early onset cataract should also lead to the suspicion of cerebrotendinous xanthomatosis and a retinitis pigmentosa to a defect of homocystein remethylation pathways. Mitochondrial and peroxisomal diseases are often responsible for sensorineural deafness.
As outlined above, unlike most genetic diseases, the diagnosis of neurometabolic diseases can be guided by dedicated biochemical analyses prior to molecular testing. In emergency, an unexplained encephalopathy must be explored using simple analyses such as plasma ammonia, lactate and homocystein. In case of confirmed hyperammonemia and/or hyperlactacidemia, specialized biochemical analyses should be performed in emergency:
amino acids chromatography on plasma and urine plus urine orotic acid for urea cycle defects; plasma acylcarnitines profile and urine organic acids chromatography for organic aciduria and fatty acids oxidation defects. Last, but not least, there are few IEM that can be diagnosed thanks to simple therapeutic tests. This is the case of patients harboring mutations in the SLC19A3 gene, which encodes the transmembrane thiamine transporter hTHTR2. Mutations in this gene cause the so--called biotin--responsive basal ganglia disease (BBGD) and lead to recurrent episodes of encephalopathy that can be life--threatening or result in severe dystonia if untreated. Brain MRI is remarkable due to the presence of lesions of the caudate nuclei and putamen, as well as the mesencephalon and cortical--subcortical areas. Treatment with high doses of biotin and thiamine can result in spectacular clinical and radiologic improvement, even in adults [11] . Autosomal dominant dopa--responsive dystonia (DRD), mainly due to mutations in the GCH1 gene that encodes GTC cyclohydrolase I, a rate--limiting step in tetrahydrobiopterin biosynthesis, is another good example. Likewise, patients who present with generalized dystonia, sometimes severely disabling, experience a dramatic and sustained response (complete or near--complete responsiveness of symptoms) to relatively low doses of orally administered levodopa [12] .
What are the neurometabolic diseases requiring an emergency treatment?
In emergency, there are 2 main situations when an IEM should be strongly considered:
unexplained acute encephalopathy and rhabdomyolysis. As detailed above, the clinical history of the patient and his/her family, simple biochemical analyses to be repeated in emergency (ammonemia, lactacidemia, homocysteinemia) and, sometimes, brain MRI are instrumental to guide the diagnostic and therefore therapeutic strategies. As mentioned above, recurrent episodes of encephalopathy with T2 hyperintensities of the caudate and putamen should prompt the administration of high doses of biotin and thiamine due to the suspicion of BBGD. In case of an encephalopathy with hyperammoniemia, a personal or familial anamnesis of recurrent confusional state and/or a metabolic trigger, the co--occurrence of digestive and neuropsychiatric symptoms, the dissociation between liver insufficiency and relatively mild cytolysis are very evocative of an urea cycle defect, and especially ornithine transcarbamylase deficiency. Plasma amino acids chromatography and urine orotic acid should be performed in emergency to identify the defect in urea cycle enzymes but should not delay the initiation of treatment. Treatment must include: a temporary (<72h in adults) protein removal from intake (oral, enteral or parenteral nutrition), a reversal of the catabolic state through caloric supplementation using IV glucose and lipids (2500 to 3000 calories minimum for women and men respectively) which often requires a central IV line, pharmacologic scavenging of excess nitrogen using sodium benzoate and/or sodium phenylbutyrate and IV arginine to replace arginine not produced by the urea cycle and prevents its deficiency from causing additional protein catabolism.
Depending on ammonia levels at baseline, the severity of the neurological status and/or the kinetics of ammonia upon medical treatment, dialysis may be necessary for a few hours to remove ammonia. For ornithine transcarbamylase deficiency, specialized genetic counseling is mandatory as the disease can be transmitted from generation to generation. As a X--linked disease, men are more severely affected than women but women can become symptomatic during pregnancy or in the post--partum period. In addition, a late onset form does not preclude more severe and early onset forms in other family members carriers of the mutation. Likewise, genetic counseling should lead to the identification of all possible family carriers, assess their protein tolerance and provide emergency recommendations during metabolic crises in order to avoid life--threatening episodes. In case of an encephalopathy with hyperlactacidemia, pyruvate levels are important to determine the lactate/pyruvate ratio : in pyruvate dehydrogenase deficiency, the ratio is normal due to concomitant elevation of pyruvicemia -a ketogenic diet as well as thiamine supplementation may be initiated in emergency, whereas in oxidative phosphorylation defects, the lactate/pyruvate ratio is elevated. Clinical features (ptosis, ophthalmoplegia, sensory neuronopathy) and/or MRI findings (Leigh syndrome, pseudo--strokes) are also important to orientate towards a mitochondrial energy deficiency. Except for status epilepticus or intractable seizures for which a ketogenic diet is indicated, there are unfortunately no drug that have proved efficacy in mitochondrial diseases. However, the initiation of some treatments must be avoided, like valproate, as they can aggravate the metabolic status. The implication of other systems (kidneys, liver) must also be considered, especially cardiac dysfunction as they can significantly worsen disease prognosis. For mutations of mitochondrial DNA, genetic counseling is also important as the mitochondrial DNA is exclusively transmitted by mothers. In case of rhabdomyolysis, besides McArdle disease (muscle glycogen phosphorylase deficiency) characterized by exercise intolerance and the "second wind" phenomenon, fatty acids oxidation defects should be ruled out because of a high mortality rate due to heart conduction defects and profound hypoglycemia. Plasma acylcarnitines profile and urine organic acids chromatography will lead to the diagnosis but should not delay an emergency treatment that primarily consists in perfusing high doses of glucose in order to stop lipolysis and provide urgent energy substrates for the liver as well as dialysis when rhabdomyolysis leads to an acute renal failure.
What are the other treatable neurometabolic diseases?
Besides these emergency situations, other neurometabolic diseases are amenable to treatments and can require genetic counseling. As stated above, any patient presenting with generalized dystonia should benefit from a therapeutic test with levodopa in the event of DRD. Moreover, in GLUT1 deficiency, SLC2A1 mutations usually occurs de novo but a dominant family history should be carefully looked for and genetic testing offered to persons at risk as treatment is available. Due to the insufficient provision of glucose to astrocytes, the disease can manifest in children with a predominant epileptic encephalopathy whereas recurrent episodes of movement disorders, especially during exercise or fast, are common when patients become adults or in late onset forms of the disease [13] . The alternative provision of energy thanks to high levels of ketone bodies, using a ketogenic diet, leads to a very good response on seizures and a partial response on movement disorders. Other therapeutic options are under development to provide alternative brain energy substrates in GLUT1 deficiency. ABCD1 mutations are in majority responsible for adrenomyeloneuropathy,
i.e. spastic paraplegia and/or peripheral neuropathy, in both men and women whereas the cerebral form of the disease, called adrenoleukodystrophy, is characterized by a severe and rapid motor and cognitive decline, which exclusively occurs in men - usually during infancy but cases have been reported up to 50 years old. Adrenal insufficiency is also predominantly seen in men. The cerebral and adrenal forms of this X--linked disease motivate a thorough genetic counseling in order to identify men under 50 years of age at risk of being carriers.
The identification of inflammatory lesions on brain MRI before symptoms onset is a good indication for bone marrow transplant that can prevent the evolution of the disease towards a devastating cerebral form. Of note, X--linked adrenoleukodystrophy is also the first neurometabolic disease for which gene therapy has recently been successful [14] .
Cerebrotendinous xanthomatosis and Niemann--Pick type C are 2 other metabolic diseases involved in complex lipids metabolism with therapeutic perspectives. In both, the association of psychiatric symptoms with spastic ataxia or cerebellar ataxia should motivate the measurements of plasma cholestanol and 7--ketocholesterol respectively. In cerebrotendinous xanthomatosis, despite the frequent occurrence of diarrhea since infancy as well as cataract during childhood or adolescence, the diagnosis is almost always done in adults. Treatment with chenodeoxycholic acid leads to the normalization of cholestanol levels within a few months as well as a rapid improvement of digestive and psychiatric symptoms. Chenodeoxycholic acid has also been reported to stabilize peripheral neuropathy on the long term and improve motor functions [15] . In Niemann--Pick type C, substrate reduction therapies, like miglustat an inhibitor of glucosylceramide synthase, reduce the accumulation of glycosphingolipids and seem to stabilize some components of the disease like oculomotor functions and swallowing abilities [16] . Other therapeutic options are under development to counteract glycosphingolipids accumulation in Niemann--Pick type C.
Reducing agents like copper or manganese chelating drugs are also the therapeutic strategies of choice in Wilson disease or SLC30A10 mutations respectively. Likewise, penicillamine or trientine increase urinary excretion of copper and can reduce hepatic, neurologic, and psychiatric findings in many symptomatic individuals as well as prevent symptoms onset in presymptomatic individuals.
Conclusion
Initially discovered and described in children, a growing number of IEM are now diagnosed in adults, especially in the field of neurology. Besides the neurometabolic diseases that usually manifest only in adults (i.e. adult polyglucosan body disease), IEM that predominantly manifest in childhood tend to have a different clinical and imaging phenotype in adults, such as CYP7B1 mutations presenting as a severe liver disease in infants but a progressive spastic paraplegia in adults [17] , explaining why adult physicians dedicated to the diagnosis and care of these patients are specifically needed. Far from being exhaustive, this outline aims at providing simple diagnostic tools and major therapeutic strategies needed to recognize and treat the most common adult neurometabolic diseases that are likely to be seen in neurology practice. The contribution of metabolism to the field of adult neurology and neurosciences is however much greater. Besides the existing blood biomarkers cited above that are progressively changing our approach to clinical diagnoses of spastic paraplegia or atypical psychiatric symptoms for example, it is likely that additional biomarkers will be identified in the soon future thanks to the development of lipidomic approaches. This may be especially true for the field of inherited spastic paraplegia as several recently identified genes are involved in the remodeling of phospholipids -SPG54 (DDHD1), SPG28 (DDHD2), SPG39 (NTE), SPG56 (CYP2U1) -and the biosynthesis of sphingolipids -SPG35 (FA2H), SPG46 (GBA2), SPG26 (B4GALNT1) -opening the way to a novel class of IEM [1, 18] . These rare diseases also shed light on mechanisms involved in common neurological diseases or symptoms such as, for spasticity, the importance of the maintenance of lipid membrane homeostasis. Another important example is the identification of heterozygous mutations in the GBA1 gene, encoding lysosomal glucocerebrosidase, as the first risk factor of sporadic Parkinson disease [19] . More than a genetic factor, it appears that the decrease of glucocerebrosidase activity itself can favor the development of a synuclein--related pathology like seen in Parkinson disease. Indeed, the accumulation of lysosomal glucosylceramides due to glucocerebrosidase deficiency seems to accelerate and stabilize soluble alpha--synuclein oligomers, which eventually convert into amyloid fibrils [20] . This has important consequences on the development of therapeutic strategies in Parkinson disease as increasing the activity of glucocerebrosidase could be neuroprotective. Single observations in IEM can also contribute to a better understanding of brain physiology. Likewise, in adult polyglucosan body disease, we showed that abnormal glycogen in astrocytes is sufficient to cause motor dysfunction and a severe leukodystrophy [21] . This comes to support an important role of not only glucose and ketone bodies in brain energy metabolism but also glycogen as suggested by other neurogenetic disorders affecting glycogen metabolism such as Lafora disease. 
